Ann: Neurotech Completes $9.0M Placement, page-29

I am not contrarian by any stretch of the imagination, that would suggest a fundamental difference in opinion. I would say that about 80% of our views align (and probably 95% on the longer term). As I have stated many times, this is not a short term game and a lot still needs to go right and a lot more money needs to be invested and raised before and FDA approval is granted for ASD alone - the idea is the SP is higher in 12-18m when the raise again. I do wish you and current holders luck, your onto a good thing. I hope I time it well to be back at the table. GLTAH.